March 4, 2020 / 10:33 PM / a month ago

BRIEF-Hikma Pharma Extends Voluntary Nationwide Recall Of Ketorolac Tromethamine Injections Due To Potential Small Particulate Presence

March 4 (Reuters) - Hikma Pharmaceuticals PLC:

* HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF KETOROLAC TROMETHAMINE INJECTION, USP 30MG/ML, 1ML FILL/2ML VIALS DUE TO POTENTIAL PRESENCE OF SMALL PARTICULATES

* HIKMA - PRODUCT BEING RECALLED DUE TO PRESENCE OF SMALL VISIBLE PARTICULATE MATTERS OF GELATINOUS/OILY NATURE THAT APPEAR BLACK IN SOME RECALLED LOTS

* HIKMA - LOTS BEING RECALLED WERE MANUFACTURED BETWEEN MARCH 22, 2018 AND FEBRUARY 21, 2019

* HIKMA - INVESTIGATED CAUSE OF PROBLEM AND DECIDED TO SUSPEND MANUFACTURING OF PRODUCT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below